Cited 3 times in
A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.date.accessioned | 2017-10-26T07:58:46Z | - |
dc.date.available | 2017-10-26T07:58:46Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1042-8194 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/152771 | - |
dc.description.abstract | Overall, more than 50% of marginal zone lymphoma (MZL) patients experience a relapse within 10 years. This phase II trial was conducted to assess the efficacy and safety of oxaliplatin-prednisone (Ox-P) chemotherapy for patients with relapsed or refractory MZL. Patients received oxaliplatin 130?mg/m(2) on day 1 and prednisone 100?mg/day on days 1-5 of each cycle. A total of 38 patients were enrolled. The median age of the 34 (16 males, 18 females) evaluated patients was 53 (range?=?27-74) years. There were seven complete responses (20.6%) and 15 partial responses (44.1%) (Overall response rate?=?64.7%). No treatment-related deaths occurred. The median progression-free survival was 14.2 months (95% CI?=?2.1-26.3 months); 3-year overall survival rate was 77.7%. Thus, salvage Ox-P chemotherapy for patients with relapsed or refractory MZL at the stated dosage and schedule showed moderate clinical activity and was considerable in very few selected patients (NCT01068392). | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Informa Healthcare | - |
dc.relation.isPartOf | LEUKEMIA & LYMPHOMA | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Drug Resistance, Neoplasm | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lymphoma, B-Cell, Marginal Zone/diagnosis* | - |
dc.subject.MESH | Lymphoma, B-Cell, Marginal Zone/drug therapy* | - |
dc.subject.MESH | Lymphoma, B-Cell, Marginal Zone/mortality | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Organoplatinum Compounds/administration & dosage | - |
dc.subject.MESH | Prednisone/administration & dosage | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Recurrence | - |
dc.subject.MESH | Retreatment | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial | - |
dc.type | Article | - |
dc.publisher.location | England | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Sung Yong Oh | - |
dc.contributor.googleauthor | Won Seog Kim | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Yee Soo Chae | - |
dc.contributor.googleauthor | Gyeong-Won Lee | - |
dc.contributor.googleauthor | Hyeon Seok Eom | - |
dc.contributor.googleauthor | Hun Mo Ryoo | - |
dc.contributor.googleauthor | Suee Lee | - |
dc.contributor.googleauthor | Seok Jin Kim | - |
dc.contributor.googleauthor | Dok Hyun Yoon | - |
dc.contributor.googleauthor | Jong Ho Won | - |
dc.contributor.googleauthor | Junshik Hong | - |
dc.contributor.googleauthor | Jinny Park | - |
dc.contributor.googleauthor | Sang-Min Lee | - |
dc.contributor.googleauthor | Jung Yong Hong | - |
dc.contributor.googleauthor | Eunkyung Park | - |
dc.contributor.googleauthor | Hyo Jung Kim | - |
dc.contributor.googleauthor | Deok-Hwan Yang | - |
dc.contributor.googleauthor | Hyo-Jin Kim | - |
dc.contributor.googleauthor | Cheolwon Suh | - |
dc.identifier.doi | 10.3109/10428194.2015.1099650 | - |
dc.contributor.localId | A01017 | - |
dc.relation.journalcode | J02165 | - |
dc.identifier.eissn | 1029-2403 | - |
dc.identifier.pmid | 26413982 | - |
dc.identifier.url | http://www.tandfonline.com/doi/full/10.3109/10428194.2015.1099650 | - |
dc.subject.keyword | Oxaliplatin | - |
dc.subject.keyword | marginal zone lymphoma | - |
dc.subject.keyword | prednisone | - |
dc.subject.keyword | refractory | - |
dc.subject.keyword | relapse | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | Kim, Jin Seok | - |
dc.citation.volume | 57 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1406 | - |
dc.citation.endPage | 1412 | - |
dc.identifier.bibliographicCitation | LEUKEMIA & LYMPHOMA, Vol.57(6) : 1406-1412, 2016 | - |
dc.date.modified | 2017-10-24 | - |
dc.identifier.rimsid | 39779 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.